RNA Inhibitor Is Shown Safe and Effective in Reducing a Wide Range of Cholesterol and Triglyceride Levels in the Blood in Mount Sinai-Led Clinical Trial
May 30, 2024
May 30, 2024
NEW YORK, May 30 -- Mount Sinai Health System issued the following news release:
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.
In addition to seeing promising prelimina . . .
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.
In addition to seeing promising prelimina . . .